BioSpace News Archive

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced the launch of an expanded access program that will allow the company to offer ganaxolone to patients with CDKL5 Deficiency Disorder who were unable to participate in the company’s Marigold Study Phase 3 clinical trial.

First patient was dosed in pivotal Phase 3 AFFINE study in October 2020

LOTIS 3 interim results highlight potential of Lonca in combination with ibrutinib in relapsed or refractory diffuse large B-cell lymphoma and mantle cell lymphoma patients

Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, presented preclinical data from its wholly-owned MALT1 inhibitor program in B-cell lymphomas at the virtual 62nd American Society of Hematology Annual Meeting.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it has initiated dosing in its Phase 1b study of ARCT-810 in patients with Ornithine Transcarbamylase

Theralase® Technologies Inc. announced that the University of British Columbia Review Ethics Board has approved the commencement of a Pivotal Phase II Non-Muscle Invasive Bladder Cancer Clinical Study to enroll and treat patients who present with Carcinoma In-Situ and who are considered Bacillus Calmette Guerin-Unresponsive or are intolerant to BCG Therapy.

NANOBIOTIX announced the start of its roadshow in connection with its intention to issue and sell, subject to market and other conditions, 6,500,000 ordinary shares of the Company in an initial public offering of American Depositary Shares, each representing one ordinary share, in the United States and a concurrent offering of ordinary shares in certain jurisdictions outside of the United States.

Once-WeeklyTwirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE)

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has been notified by the U.S. Food and Drug Administration (FDA) that a clinical hold has been placed on patient enrollment and dosing in an ongoing Phase 1/2 dose-escalation clinical trial evaluating BPX-601 in patients with previously treated metastatic pancreatic or prostate cancer.

Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced Kevin Muir has joined the company as Vice President of Commercial Operations.